» Download Public Reports
13 reports
- Company report
- March 2011
- 6 pages
... D program in the pipeline. While other companies in the drug delivery market space have obtained such partnerships or grants in the past, there can be no assurance that the company will be able to sign ...
March 2011
... Proprietary oral and inhalation technologies and expertise Business model built around in-house and partnered products Full service drug delivery provider Alliances with aenova for oral manufacturing ...
March 2011
... Or new r&d program in the pipeline. While other companies in the drug delivery market space have obtained such partnerships or grants in the past, there can be no assurance that the company will be able ...
July 2012
... Ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. Psivida is currently focused on treatment of chronic ...
November 2011
... Countries Growing number of acute and chronic diseases Accelerating pace in drug development Growth in biotech drugs and generics Outsourcing trend of drug delivery and primary packaging ...
June 2011
... Take or do not respond well to oral medication, and in addition vitaros with its nexact drug delivery technology rapidly and efficiently delivers the active ingredient (alprostadil) to the penis ...
December 2011
... Beds facility 50+ Studies completed [n=40] Key equipments: Lcms 4 Generics Dosage forms P-iv anda S Ftf opportunities Api & drug intermediates drug ...
June 2009
... And stifles innovation Discourages investors May prove to be the major bottleneck to viable commercialization nanomedicine industry Key players and clients Business drivers Business models ...